Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.45 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13561313 | 0.92 | ALDH1A1 (0.55) | LRRK2CA1CA2ALDH1A1MAPT | |
| SCHEMBL13973915 | 0.88 | KDR (0.51) | LRRK2CA1CA2ALDH1A1MAPT | |
| SCHEMBL20714579 | 0.85 | MAPT (0.54) | LRRK2ALDH1A1MAPTSMN1; SMN2RET | |
| SCHEMBL13973913 | 0.85 | CES1 (0.67) | CES1LRRK2CA1CA2ALDH1A1 | |
| SCHEMBL9472806 | 0.83 | CES1 (0.67) | CES1LRRK2CA1CA2ALDH1A1 | |
| SCHEMBL9472812 | 0.83 | CES1 (0.67) | CES1LRRK2CA1CA2ALDH1A1 | |
| SCHEMBL13973919 | 0.82 | CAPN9 (0.46) | LRRK2CA1CA2ALDH1A1MAPT | |
| SCHEMBL30978130 | 0.77 | MAPT (0.52) | LRRK2ALDH1A1MAPTSMN1; SMN2RET | |
| SCHEMBL12444419 | 0.74 | CES1 (0.65) | CES1LRRK2CA1CA2ALDH1A1 | |
| SCHEMBL23347502 | 0.74 | MAPT (0.54) | LRRK2ALDH1A1MAPTSMN1; SMN2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859783-B2 | Indirubin-3′-oxime derivatives as potent cyclin dependent kinase inhibitors | ANYGEN CO., LTD. (KR) | 2014-10-14 | — | — | US | disclosed |
| US-20120295948-A1 | INDIRUBIN-3'-OXIME DERIVATIVES AS POTENT CYCLIN DEPENDENT KINASE INHIBITORS | ANYGEN CO., LTD. (KR) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295948-A1 | INDIRUBIN-3'-OXIME DERIVATIVES AS POTENT CYCLIN DEPENDENT KINASE INHIBITORS | CCNI, CCNK, CDK2 | CES1 2418/4885LRRK2 2374/4885CA1 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.